Olmetec Use In Pregnancy & Lactation

There is no experience with the use of olmesartan medoxomil in pregnant women.
However, drugs that act directly on the renin-angiotensin system administered during the 2nd and 3rd trimesters of pregnancy have been reported to cause foetal and neonatal injury (hypotension, renal dysfunction, oliguria and/or anuria, oligohydramnios, skull hypoplasia, intrauterine growth retardation, lung hypoplasia, facial abnormalities, limb contracture) and even death.
Thus, as for any drug in this class, olmesartan medoxomil is contraindicated during the 2nd and 3rd trimesters of pregnancy.
In addition, olmesartan medoxomil must not be used during the 1st trimester of pregnancy. If pregnancy occurs during therapy, olmesartan medoxomil must be discontinued as soon as possible.
Olmesartan is excreted in the milk of lactating rats but it is not known whether olmesartan is excreted in human milk.
Mothers must not breastfeed if they are taking Olmetec.